Advanced prototype for continuous crystal sizing

在药品剂型的制造中，控制晶体粒度分布是必不可少的。特别是，通过Eupraxia制药公司开发的新技术，获得狭窄的尺寸分布对于精确控制治疗剂的释放特征**至关重要。目前的工作流程**需要获得适当粒径的微晶颗粒，这对新型抗炎疗法的扩大和生产构成了重大障碍。该提案建立在成功完成ENGAGE**拨款的基础上，旨在共同设计和鉴定一种新型晶体施胶装置。完成的设备必须能够在连续工作流程中对研磨晶体种群进行尺寸分离。该设备将测试一种新型脉冲流筛概念的可行性，并检查放大和设计的潜力，以及为制造环境建造的大型装置。

Control of crystallite particle size distribution is essential in the manufacturing of pharmaceutical dosage**forms. In particular, obtaining a narrow size distribution is essential to enable precise control of release profile**of therapeutic agent through novel technology developed by Eupraxia pharmaceuticals. The present workflow**needed to obtain crystallite particles of the appropriate particle size presents a significant barrier to scale up and**manufacturing of a novel anti-inflammatory therapy. This proposal builds on a successful completed ENGAGE**grant and aims to codesign and qualify a novel crystal sizing apparatus. The completed device must be capable**of size segregation of a milled crystal population in a continuous workflow. This device will test the feasibility**of a novel pulse-flow sieving concept and examine the potential for scale-up and design and a large-scale unit**built for a manufacturing environment.